Apr 2 |
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
|
Mar 1 |
Does Kiniksa Pharmaceuticals, Ltd. (KNSA) Have the Potential to Rally 32.45% as Wall Street Analysts Expect?
|
Mar 1 |
Kiniksa Pharmaceuticals Full Year 2023 Earnings: Beats Expectations
|
Mar 1 |
Chief Medical Officer John Paolini Sells 10,156 Shares of Kiniksa Pharmaceuticals Ltd (KNSA)
|
Feb 29 |
Are You Looking for a Top Momentum Pick? Why Kiniksa Pharmaceuticals, Ltd. (KNSA) is a Great Choice
|
Feb 29 |
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2023 Earnings Call Transcript
|
Feb 28 |
Kiniksa Pharmaceuticals Ltd. (KNSA) Q4 2023 Earnings Call Transcript
|
Feb 28 |
Kiniksa Pharmaceuticals, Ltd. (KNSA) Q4 Earnings and Revenues Surpass Estimates
|
Feb 28 |
Kiniksa Pharmaceuticals Ltd (KNSA) Reports Strong Revenue Growth in Q4 and Full-Year 2023
|
Feb 28 |
Kiniksa Pharmaceuticals GAAP EPS of $0.35 beats by $0.49, revenue of $83.4M beats by $11.13M
|